newsfilter
← Latest News
GlobeNewswire·

Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates

DENALI Part 1b survival data strengthen azenosertib's position as the potential first-in-class oral, non-chemotherapy, non-ADC therapy in pivotal development for Cyclin E1-positive PROCDENALI Part 2c enrollment